Replimune/$REPL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Ticker
$REPL
Sector
Primary listing
Employees
479
Headquarters
Website
Replimune Metrics
BasicAdvanced
$452M
-
-$3.60
0.67
-
Price and volume
Market cap
$452M
Beta
0.67
52-week high
$14.80
52-week low
$2.68
Average daily volume
3.1M
Financial strength
Current ratio
6.94
Quick ratio
6.802
Long term debt to equity
21.468
Total debt to equity
22.668
Interest coverage (TTM)
-36.94%
Profitability
EBITDA (TTM)
-287.16
Effective tax rate (TTM)
-0.17%
Management effectiveness
Return on assets (TTM)
-36.45%
Return on equity (TTM)
-73.44%
Valuation
Price to book
1.34
Price to tangible book (TTM)
1.34
Price to free cash flow (TTM)
-1.977
Free cash flow yield (TTM)
-50.58%
Free cash flow per share (TTM)
-2.928
Growth
Earnings per share change (TTM)
11.82%
3-year earnings per share growth (CAGR)
12.65%
What the Analysts think about Replimune
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Bulls say / Bears say
The BLA priority review for RP1 plus nivolumab remains on schedule, with the FDA’s manufacturing inspections and late-cycle review now complete, supporting regulatory readiness ahead of the July 22, 2025 PDUFA date (GlobeNewswire).
Replimune has established its full commercial infrastructure—including a fully hired and trained field team, distribution channels, and key state licensing—in preparation for the anticipated RP1 launch, demonstrating strong launch-readiness (GlobeNewswire).
The global Phase 3 IGNYTE-3 trial of RP1 in combination with nivolumab is actively enrolling across over 100 planned sites, maintaining momentum for the pivotal study despite recent setbacks (GlobeNewswire).
On July 22, 2025, the FDA issued a Complete Response Letter for the RP1 Biologics License Application, indicating the application cannot be approved in its present form and highlighting that the IGNYTE trial lacked adequate evidence of effectiveness (GlobeNewswire).
Shares of Replimune fell approximately 75% following the CRL announcement, reflecting severe market reaction and heightened investor litigation risk (Barron's).
The CRL cited inadequacies in the IGNYTE trial design and patient heterogeneity, necessitating a Type A meeting with the FDA and potential redesign of confirmatory studies, likely delaying approval timelines (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Replimune Financial Performance
Revenues and expenses
Replimune Earnings Performance
Company profitability
Replimune News
AllArticlesVideos
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
Business Wire1 week ago
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL
Business Wire2 weeks ago
NASDAQ: REPL: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Replimune Group, Inc.
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Replimune stock?
Replimune (REPL) has a market cap of $452M as of September 17, 2025.
What is the P/E ratio for Replimune stock?
The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of September 17, 2025.
Does Replimune stock pay dividends?
No, Replimune (REPL) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Replimune dividend payment date?
Replimune (REPL) stock does not pay dividends to its shareholders.
What is the beta indicator for Replimune?
Replimune (REPL) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.